These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26578722)

  • 41. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results.
    Ohguri T; Imada H; Narisada H; Yahara K; Morioka T; Nakano K; Miyaguni Y; Korogi Y
    Int J Hyperthermia; 2009 Mar; 25(2):160-7. PubMed ID: 19337916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
    Lorenzen S; Knorrenschild JR; Pauligk C; Hegewisch-Becker S; Seraphin J; Thuss-Patience P; Kopp HG; Dechow T; Vogel A; Luley KB; Pink D; Stahl M; Kullmann F; Hebart H; Siveke J; Egger M; Homann N; Probst S; Goetze TO; Al-Batran SE
    Int J Cancer; 2020 Nov; 147(9):2493-2502. PubMed ID: 32339253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
    Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ
    J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.
    Reck M; Jagos U; Grunwald F; Kaukel E; Koschel G; von Pawel J; Hessler S; Gatzemeier U
    Lung Cancer; 2003 Jan; 39(1):63-9. PubMed ID: 12499096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
    Kim KB; Sosman JA; Fruehauf JP; Linette GP; Markovic SN; McDermott DF; Weber JS; Nguyen H; Cheverton P; Chen D; Peterson AC; Carson WE; O'Day SJ
    J Clin Oncol; 2012 Jan; 30(1):34-41. PubMed ID: 22124101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
    Hauke RJ; Infante JR; Rubin MS; Shih KC; Arrowsmith ER; Hainsworth JD
    Melanoma Res; 2013 Dec; 23(6):468-73. PubMed ID: 23969699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
    Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
    J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
    Bafaloukos D; Linardou H; Aravantinos G; Papadimitriou C; Bamias A; Fountzilas G; Kalofonos HP; Kosmidis P; Timotheadou E; Makatsoris T; Samantas E; Briasoulis E; Christodoulou C; Papakostas P; Pectasides D; Dimopoulos AM
    BMC Med; 2010 Jan; 8():3. PubMed ID: 20055981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Von Pawel J; Reck M; Jameson MB; Rosenthal MA; Sullivan R; Gibbs D; Mainwaring PN; Serke M; Lafitte JJ; Chouaid C; Freitag L; Quoix E
    Br J Cancer; 2008 Dec; 99(12):2006-12. PubMed ID: 19078952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
    J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.